Search research articles
Contact Us
Filters
Showing results (261-270 of 686) with videos related to
Page
of 69
Sort By:
The Oncologist
|
March 17, 2021
Overview of Ocular Side Effects of Selinexor
Nagham Al-Zubidi, Dan S Gombos, David S Hong, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 13, 2017
Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer
Takeo Fujii, Naoko Matsuda, Miho Kono, et al.
Cancer Medicine
|
February 24, 2024
Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors
Niamh Coleman, Bettzy Stephen, Siqing Fu, et al.
Cancer
|
August 13, 2011
Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers
Kanwal P S Raghav, Leonel F Hernandez-Aya, Xiudong Lei, et al.
Cancer
|
June 22, 2010
Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer
Laura S Dominici, Viviana M Negron Gonzalez, Aman U Buzdar, et al.
Molecular Cancer Therapeutics
|
July 7, 2023
Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Funda Meric-Bernstam, Emiliano Calvo, Keun Seok Lee, et al.
Oncotarget
|
July 1, 2014
Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer
Shuying Liu, Xiaolong Meng, Huiqin Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 23, 2026
Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients With Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase Studies
Keun-Wook Lee, Elena Elimova, Do-Youn Oh, et al.
The Oncologist
|
September 4, 2007
Trends for inflammatory breast cancer: is survival improving?
Ana M Gonzalez-Angulo, Bryan T Hennessy, Kristine Broglio, et al.
Molecular Cancer Therapeutics
|
September 30, 2010
Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer
David Luyimbazi, Argun Akcakanat, Priscilla F McAuliffe, et al.
Page
of 69
Search research articles
Search
Showing results (261-270 of 686) with videos related to
Sort By:
Page
of 69
The Oncologist
|
March 17, 2021
Overview of Ocular Side Effects of Selinexor
Nagham Al-Zubidi, Dan S Gombos, David S Hong, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 13, 2017
Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer
Takeo Fujii, Naoko Matsuda, Miho Kono, et al.
Cancer Medicine
|
February 24, 2024
Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors
Niamh Coleman, Bettzy Stephen, Siqing Fu, et al.
Cancer
|
August 13, 2011
Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers
Kanwal P S Raghav, Leonel F Hernandez-Aya, Xiudong Lei, et al.
Cancer
|
June 22, 2010
Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer
Laura S Dominici, Viviana M Negron Gonzalez, Aman U Buzdar, et al.
Molecular Cancer Therapeutics
|
July 7, 2023
Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Funda Meric-Bernstam, Emiliano Calvo, Keun Seok Lee, et al.
Oncotarget
|
July 1, 2014
Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer
Shuying Liu, Xiaolong Meng, Huiqin Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 23, 2026
Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients With Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase Studies
Keun-Wook Lee, Elena Elimova, Do-Youn Oh, et al.
The Oncologist
|
September 4, 2007
Trends for inflammatory breast cancer: is survival improving?
Ana M Gonzalez-Angulo, Bryan T Hennessy, Kristine Broglio, et al.
Molecular Cancer Therapeutics
|
September 30, 2010
Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer
David Luyimbazi, Argun Akcakanat, Priscilla F McAuliffe, et al.
Page
of 69